Article | Published:

Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia

Nature volume 513, pages 512516 (25 September 2014) | Download Citation


Mutations that deregulate Notch1 and Ras/phosphoinositide 3 kinase (PI3K)/Akt signalling are prevalent in T-cell acute lymphoblastic leukaemia (T-ALL), and often coexist. Here we show that the PI3K inhibitor GDC-0941 is active against primary T-ALLs from wild-type and KrasG12D mice, and addition of the MEK inhibitor PD0325901 increases its efficacy. Mice invariably relapsed after treatment with drug-resistant clones, most of which unexpectedly had reduced levels of activated Notch1 protein, downregulated many Notch1 target genes, and exhibited cross-resistance to γ-secretase inhibitors. Multiple resistant primary T-ALLs that emerged in vivo did not contain somatic Notch1 mutations present in the parental leukaemia. Importantly, resistant clones upregulated PI3K signalling. Consistent with these data, inhibiting Notch1 activated the PI3K pathway, providing a likely mechanism for selection against oncogenic Notch1 signalling. These studies validate PI3K as a therapeutic target in T-ALL and raise the unexpected possibility that dual inhibition of PI3K and Notch1 signalling could promote drug resistance in T-ALL.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


Primary accessions

Gene Expression Omnibus

Data deposits

Expression profiling data have been deposited in the Gene Expression Omnibus under accession number GSE48260.


  1. 1.

    , & Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies. J. Pathol. 223, 263–274 (2011)

  2. 2.

    et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 114, 647–650 (2009)

  3. 3.

    & The NOTCH signaling pathway: role in the pathogenesis of T-cell acute lymphoblastic leukemia and implication for therapy. Ther. Adv. Hematol. 4, 199–210 (2013)

  4. 4.

    et al. Clonal evolution enhances leukemia-propagating cell frequency in T cell acute lymphoblastic leukemia through Akt/mTORC1 pathway activation. Cancer Cell 25, 366–378 (2014)

  5. 5.

    et al. Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. Cancer Cell 24, 766–776 (2013)

  6. 6.

    et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nature Med. 13, 1203–1210 (2007)

  7. 7.

    et al. Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. J. Clin. Oncol. 31, 4333–4342 (2013)

  8. 8.

    et al. Negative prognostic impact of PTEN mutation in pediatric T-cell acute lymphoblastic leukemia. Leukemia 24, 239–242 (2010)

  9. 9.

    et al. Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J. Exp. Med. 208, 653–661 (2011)

  10. 10.

    et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J. Med. Chem. 51, 5522–5532 (2008)

  11. 11.

    et al. Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents. Proc. Natl Acad. Sci. USA 107, 5106–5111 (2010)

  12. 12.

    et al. Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo. Blood (2013)

  13. 13.

    et al. Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras. Nature 461, 411–414 (2009)

  14. 14.

    et al. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc. Natl Acad. Sci. USA 106, 18351–18356 (2009)

  15. 15.

    , , & Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration. Cancer Chemother. Pharmacol. 59, 671–679 (2007)

  16. 16.

    et al. Hes1 is a critical but context-dependent mediator of canonical Notch signaling in lymphocyte development and transformation. Immunity 33, 671–684 (2010)

  17. 17.

    et al. Notch-1 mutations are secondary events in some patients with T-cell acute lymphoblastic leukemia. Clin. Cancer Res. 13, 6964–6969 (2007)

  18. 18.

    et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322, 1377–1380 (2008)

  19. 19.

    , & Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget 2, 336–346 (2011)

  20. 20.

    , , , & Notch1 regulates AKT activation loop (Thr308) dephosphorylation through modulation of the PP2A phosphatase in PTEN-null T-cell acute lymphoblastic leukemia cells. J. Biol. Chem. 288, 22836–22848 (2013)

  21. 21.

    et al. Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. J. Exp. Med. 208, 1595–1603 (2011)

  22. 22.

    & Targeting the Notch pathway: twists and turns on the road to rational therapeutics. J. Clin. Oncol. 30, 2418–2420 (2012)

  23. 23.

    et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481, 157–163 (2012)

  24. 24.

    et al. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nature Med. 19, 368–371 (2013)

  25. 25.

    & NOTCH and PI3K-AKT pathways intertwined. Cancer Cell 12, 411–413 (2007)

  26. 26.

    , & Oncogenic and tumor suppressor functions of Notch in cancer: it’s NOTCH what you think. J. Exp. Med. 208, 1931–1935 (2011)

  27. 27.

    et al. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev. 25, 1628–1640 (2011)

  28. 28.

    , , & Versatile retroviral vectors for potential use in gene therapy. Gene Ther. 1, 136–138 (1994)

  29. 29.

    et al. Oncogenic forms of NOTCH1 lacking either the primary binding site for RBP-Jκ or nuclear localization sequences retain the ability to associate with RBP-Jκ and activate transcription. J. Biol. Chem. 272, 11336–11343 (1997)

  30. 30.

    et al. Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling. Mol. Cell. Biol. 23, 655–664 (2003)

  31. 31.

    et al. Mastermind critically regulates Notch-mediated lymphoid cell fate decisions. Blood 104, 1696–1702 (2004)

  32. 32.

    BLAT—the BLAST-like alignment tool. Genome Res. 12, 656–664 (2002)

  33. 33.

    et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 5, R80 (2004)

Download references


This work was supported by grants from the William Lawrence and Blanche Hughes Foundation to J.C.A. and K.S.; by Specialized Center of Research (SCOR) awards 7019 and 7703 from the Leukaemia and Lymphoma Society of America; by National Institutes of Health grants R37 CA72614 and R01 CA180037 (to K.S.), K99 CA157950 (to M.D.), K08 CA134649 (to Q.L.) and P01 CA119070 (to J.C.A. and W.S.P.), and by the ALSAC of St. Jude Children’s Research Hospital (J.R.D.). K.A. is supported by the Ohio Supercomputer Center (#PAS0425) and is an Ohio Cancer Research Associate (#GRT00024299); and J.X received a Research Fellowship from the American Cancer Society (ACS). K.S. is an ACS Research Professor. We are grateful to T. Jacks and D. Tuveson for KrasG12D mice; to L. Wolff for the MOL4070 virus; and to D. Largaespada and G. Narla for sharing their advice and expertise.

Author information


  1. Department of Pediatrics and Benniof Children’s Hospital, University of California, San Francisco, California 94143, USA

    • Monique Dail
    • , Jason Wong
    • , Jessica Lawrence
    • , Daniel O’Connor
    • , Jin Xu
    •  & Kevin Shannon
  2. Department of Pathology, St Jude Children’s Research Hospital, Memphis, Tennessee 38105, USA

    • Joy Nakitandwe
    • , Shann-Ching Chen
    •  & James R. Downing
  3. Department of Translational Oncology, Genentech Inc., South San Francisco, California 94080, USA

    • Leslie B. Lee
    •  & Deepak Sampath
  4. Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University, Columbus, Ohio 43210, USA

    • Keiko Akagi
  5. Division of Haematology/Oncology, Department of Medicine, University of Michigan, Ann Arbor, Michigan 48109, USA

    • Qing Li
  6. Department of Pathology, Brigham & Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA

    • Jon C. Aster
  7. Abramson Family Cancer Research Institute and the Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA

    • Warren S. Pear


  1. Search for Monique Dail in:

  2. Search for Jason Wong in:

  3. Search for Jessica Lawrence in:

  4. Search for Daniel O’Connor in:

  5. Search for Joy Nakitandwe in:

  6. Search for Shann-Ching Chen in:

  7. Search for Jin Xu in:

  8. Search for Leslie B. Lee in:

  9. Search for Keiko Akagi in:

  10. Search for Qing Li in:

  11. Search for Jon C. Aster in:

  12. Search for Warren S. Pear in:

  13. Search for James R. Downing in:

  14. Search for Deepak Sampath in:

  15. Search for Kevin Shannon in:


M.D., J.R.D., D.S. and K.S. designed experiments and analysed the data. M.D., J.W., J.L., D.O’C., J.N. and L.B.L. performed experiments. S.-C.C. and K.A. provided bioinformatics analysis. J.X., J.C.A., W.S.P., Q.L. and D.S. provided reagents. J.C.A., W.S.P., J.R.D. and D.S. provided conceptual advice. M.D. and K.S. wrote the manuscript.

Competing interests

D.S. and L.B.L. are fulltime employees of Genentech Inc.

Corresponding author

Correspondence to Kevin Shannon.

Extended data

About this article

Publication history





Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.